Sign in to view content

Brolucizumab for the Treatment of Visual Impairment Due to Diabetic Macular Edema: 52-Week Results From the KESTREL and KITE Studies

David M. Brown, MD

Video
Published 2021

Related

Real World Experience of Brolucizumab for Persistent Macular Fluid in Neovascular Age-Related Macular Degeneration After Prior Anti-VEGF Treatments
Rehan M. Hussain, MD
Annual Meeting Talks
2021
Phase IIIb TALON study of brolucizumab versus aflibercept in a matched treat-and-extend regimen to treat neovascular AMD: 32-week primary outcomes
Carl D. Regillo, MD
Annual Meeting Talks
2022
Brolucizumab in HAWK/HARRIER: Outcomes, Efficacy, & Dosing Status – Everything You Need to Know!
David M. Brown, MD
Updates from the Field
2018

Category: Diabetic Retinopathy

See more